Skip to main content
NCNA
NASDAQ Life Sciences

NuCana CEO Discloses 12% Stake, Including Billions in Vested Options, Amidst Late 13D Filing

Analysis by Wiseek.ai
Sentiment info
Positive
Importance info
8
Price
$1.74
Mkt Cap
$7.741M
52W Low
$1.74
52W High
$268
Market data snapshot near publication time

summarizeSummary

NuCana's CEO, Hugh S. Griffith, has disclosed a 12.0% beneficial ownership stake, largely comprising vested and exercisable stock options, in a belated Schedule 13D filing.


check_boxKey Events

  • CEO Discloses 12.0% Beneficial Ownership

    Hugh S. Griffith, CEO of NuCana plc, reported a 12.0% beneficial ownership stake in the company.

  • Significant Vested Options

    This ownership includes 2,828,696,864 ordinary shares from stock options, all of which are vested and exercisable within 60 days. These options were granted as compensation with very low exercise prices.

  • Late Filing with Mitigating Circumstances

    The Schedule 13D was filed after the deadline for an event on June 20, 2025, with the delay attributed to administrative oversight and the CEO's serious illness.

  • Strong Alignment of Interests

    The CEO's substantial stake, particularly with the stock trading at its 52-week low, indicates strong conviction and aligns his financial interests with the company's long-term success.


auto_awesomeAnalysis

The filing reveals NuCana plc CEO Hugh S. Griffith's substantial beneficial ownership of 12.0% of the company's ordinary shares, primarily through deeply in-the-money stock options that are immediately exercisable. This significant stake, reported while the stock trades at its 52-week low, signals strong conviction from the company's leader and aligns his interests with long-term shareholder value. While the Schedule 13D was filed significantly after its due date, the explanation citing serious illness provides context. The options, granted as compensation, represent a substantial personal financial interest for the CEO in the company's future performance.

At the time of this filing, NCNA was trading at $1.74 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.7M. The 52-week trading range was $1.74 to $268.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed NCNA - Latest Insights

NCNA
Mar 19, 2026, 4:23 PM EDT
Filing Type: 20-F
Importance Score:
8
NCNA
Mar 19, 2026, 4:01 PM EDT
Source: GlobeNewswire
Importance Score:
8
NCNA
Mar 18, 2026, 6:39 PM EDT
Filing Type: SCHEDULE 13D
Importance Score:
8
NCNA
Jan 06, 2026, 8:12 AM EST
Filing Type: 6-K
Importance Score:
7